IFN-Free, All Oral Treatment for Hepatitis C Demonstrates Impressive Response Rate

Prof. Kazuaki Chayama Combination therapy of Daklinza (daclatasvir) and Sunvepra (asunaprevir) demonstrated an 89.1% response rate in a domestic PIII clinical trial in hepatitis C patients previously untreated with interferon (IFN), a researcher says. Kazuaki Chayama, professor at the Department...read more